{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:20:00Z","timestamp":1791944400118,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA046677"],"award-info":[{"award-number":["R01-CA046677"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA179542"],"award-info":[{"award-number":["R01-CA179542"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.canlet.2021.09.020","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T11:11:58Z","timestamp":1632395518000},"page":"164-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin"],"prefix":"10.1016","volume":"522","author":[{"given":"Sohag","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0909-1629","authenticated-orcid":false,"given":"Matthew B.","family":"Utter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7753-6290","authenticated-orcid":false,"given":"Maria A.","family":"Frias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.09.020_bib1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1947601910392989","article-title":"Regulation of G1 cell cycle progression: distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s)","volume":"1","author":"Foster","year":"2010","journal-title":"Genes Canc."},{"key":"10.1016\/j.canlet.2021.09.020_bib2","first-page":"73","article-title":"Cell cycle control and cancer","volume":"96","author":"Sherr","year":"2000","journal-title":"Harvey Lect."},{"key":"10.1016\/j.canlet.2021.09.020_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-437X(01)00263-5","article-title":"Regulation of G(1) cell-cycle progression by oncogenes and tumor suppressor genes","volume":"12","author":"Ho","year":"2002","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2021.09.020_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0955-0674(95)80067-0","article-title":"What is the restriction point?","volume":"7","author":"Zetterberg","year":"1995","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2021.09.020_bib5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1073\/pnas.71.4.1286","article-title":"A restriction point for control of normal animal cell proliferation","volume":"71","author":"Pardee","year":"1974","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.09.020_bib6","doi-asserted-by":"crossref","first-page":"26709","DOI":"10.1074\/jbc.R200013200","article-title":"Regulation, restriction, and reminiscences","volume":"277","author":"Pardee","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.09.020_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074157","article-title":"Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle","volume":"8","author":"Saqcena","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2021.09.020_bib8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1074\/jbc.M116.757864","article-title":"A late G1 lipid checkpoint that is dysregulated in clear cell renal carcinoma cells","volume":"292","author":"Patel","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2021.09.020_bib9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0955-0674(97)80076-2","article-title":"The restriction point and control of cell proliferation","volume":"9","author":"Planas-Silva","year":"1997","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.canlet.2021.09.020_bib10","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.09.020_bib11","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.4161\/cc.10.22.18124","article-title":"High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1","volume":"10","author":"Yellen","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2021.09.020_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2015.01.043","article-title":"Rapamycin-induced G1 cell cycle arrest employs both TGF-\u03b2 and Rb pathways","volume":"360","author":"Chatterjee","year":"2015","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2021.09.020_bib13","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.onc.1210721","article-title":"Defective TGF-\u03b2 signaling sensitizes human cancer cells to rapamycin","volume":"27","author":"Gadir","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.09.020_bib14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1080\/15384101.2015.1046653","article-title":"Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle","volume":"14","author":"Saqcena","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2021.09.020_bib15","first-page":"1","article-title":"Cell cycle status dictates effectiveness of rapamycin","author":"Gan","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2021.09.020_bib16","first-page":"3340","article-title":"Transforming growth factor \u03b21 increases the stability of p21\/WAF1\/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells","volume":"63","author":"Gong","year":"2003","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.020_bib17","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1128\/MCB.22.9.2993-3002.2002","article-title":"Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor \u03b2-mediated G1 arrest","volume":"22","author":"Ciarallo","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.09.020_bib18","first-page":"882","article-title":"Can defective TGF-\u03b2 signaling be an Achilles heel in human cancer?","volume":"27","author":"Foster","year":"2008","journal-title":"Chin. J. Canc."},{"key":"10.1016\/j.canlet.2021.09.020_bib19","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1541-7786.MCR-12-0679","article-title":"Suppression of AKT phosphorylation restores rapamycin-based synthetic lethality in SMAD4-defective pancreatic cancer cells","volume":"11","author":"LeGendre","year":"2013","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.020_bib20","first-page":"229","article-title":"Concomitant presence of p16\/cyclin-dependent kinase 4 and cyclin D\/cyclin-dependent kinase 4 complexes in LNCaP prostatic cancer cell line","volume":"88","author":"Itoh","year":"1997","journal-title":"Jpn. J. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.020_bib21","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1097\/JTO.0b013e3182a46c0c","article-title":"CDKN2A\/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer","volume":"8","author":"Tam","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2021.09.020_bib22","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1158\/1535-7163.MCT-09-0906","article-title":"Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein","volume":"9","author":"Yoshida","year":"2010","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.09.020_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0022-1759(91)90114-U","article-title":"An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT","volume":"142","author":"Roehm","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.canlet.2021.09.020_bib24","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","article-title":"Mutation analysis of 24 known cancer genes in the NCI-60 cell line set","volume":"5","author":"Ikediobi","year":"2006","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.09.020_bib25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.020_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of genetic and epigenetic alterations of CDKN2A (p16INK4a) in cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2021.09.020_bib27","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.4161\/cc.10.15.16776","article-title":"The meaning of p16INK4a expression in tumors: functional significance, clinical associations and future developments","volume":"10","author":"Witkiewicz","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2021.09.020_bib28","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yexmp.2006.07.001","article-title":"Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer","volume":"81","author":"Agrawal","year":"2006","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.canlet.2021.09.020_bib29","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1038\/sj.onc.1205524","article-title":"p14ARF regulates E2F activity","volume":"21","author":"Mason","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.09.020_bib30","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1158\/0008-5472.CAN-08-0121","article-title":"A small-molecule E2F inhibitor blocks growth in a melanoma culture model","volume":"68","author":"Ma","year":"2008","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.020_bib31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.molcel.2020.08.020","article-title":"Integrating old and new paradigms of G1\/S control","volume":"80","author":"Rubin","year":"2020","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2021.09.020_bib32","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in cancer","volume":"19","author":"Kent","year":"2019","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2021.09.020_bib33","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature14190","article-title":"Nutrient-sensing mechanisms and pathways","volume":"517","author":"Efeyan","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.09.020_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"10.1016\/j.canlet.2021.09.020_bib35","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1128\/MCB.00782-08","article-title":"Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin","volume":"29","author":"Toschi","year":"2009","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.09.020_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-15-0720","article-title":"The enigma of rapamycin dosage","volume":"15","author":"Mukhopadhyay","year":"2016","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.09.020_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trecan.2016.03.008","article-title":"Emerging role of mTOR in the response to cancer therapeutics","volume":"2","author":"Ilagan","year":"2016","journal-title":"Trends Canc."},{"key":"10.1016\/j.canlet.2021.09.020_bib38","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.18632\/aging.100422","article-title":"Molecular damage in cancer: an argument for mTOR-driven aging","volume":"3","author":"Blagosklonny","year":"2011","journal-title":"Aging"},{"key":"10.1016\/j.canlet.2021.09.020_bib39","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ccr.2012.02.014","article-title":"Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate","volume":"21","author":"Ward","year":"2012","journal-title":"Canc. Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:59:42Z","timestamp":1759593582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521004675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":39,"alternative-id":["S0304383521004675"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.020","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}